N/A Completed N=54

The Effect of Isotretinoin on the Etonogestrel Contraceptive Implant

Contraception

Source: ClinicalTrials.gov NCT02967055 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Aug 2020

Primary outcomePrimary: Serum Etonogestrel (ENG) Level — 243.3 pg/mL

Summary

This exploratory study will fill a knowledge gap regarding the pharmacokinetic effects of isotretinoin on the etonogestrel (ENG) contraceptive implant.

Outcome Measures

Outcome	Result	p-value
PRIMARY Serum Etonogestrel (ENG) Level	145.4	—

Eligibility Criteria

Inclusion Criteria

Have a secondary form of non-hormonal contraception or abstain during isotretinoin therapy and four weeks afterwards
Have at least two negative pregnancy tests at least 19 days apart prior to initiating isotretinoin therapy
Have normal baseline laboratory evaluation including liver function tests, basic metabolic panel, and complete blood count
Willing to abstain from taking any Vitamin A supplement during the study period
Have a Body Mass Index (BMI) >= 18.5

Exclusion Criteria

Currently breastfeeding
Known contraindications to isotretinoin
Currently taking any known cytochrome P-450 3A4 enzyme inducers or inhibitors

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02967055). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.